EUVIMEDEUVIMED entdecken
Crossref

Serum IL-6, sIL-6R, and the IFN-γ/IL-10 ratio as novel predictors of treatment resistance in proliferative lupus nephritis

Liu Liu, Yating Luo, Huiyu Yuan

Journal of Medical Biochemistry · 2026 · (00) · 161-161

DOI: 10.5937/jomb0-63722 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Biochemistry, 2026. Verfasst von Liu Liu und 2 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proliferative lupus nephritis (LN) exhibits heterogeneous treatment responses. While serum cytokines reflect inflammation, their prognostic utility for predicting long-term renal outcomes remains underexplored. We investigated whether a pre-treatment serum cytokine panel could identify patients at risk for treatment failure Methods: In this prospective observational cohort, we enrolled 112 treatment-naïve patients with biopsy-proven Class III/IV (±V) LN. Serum levels of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), Interferon-gamma (IFN-g), and interleukin-10 (IL-10) were measured at baseline (T0) and 6 months post-induction (T6) via high-sensitivity electrochemiluminescence. The primary composite endpoint was "treatment failure" by 24 months, defined as failure to achieve renal response (complete/partial) at 12 months or a ≥ 40% decline in estimated glomerular filtration rate (eGFR).

Results

Thirty-two patients (28.6%) met the treatment failure endpoint. At T0, non-responders exhibited significantly higher median levels of IL-6 (12.8 vs 5.1 pg/ mL, p<0.001), sIL-6R (45.3 vs. 28.7 ng/mL, p=0.002), and the IFN-g/IL-10 ratio (3.4 vs 1.1, p<0.001). In multivariable Cox regression adjusted for histological indices and baseline eGFR, an elevated IFN-g/IL-10 ratio (Hazard Ratio [HR] 3.8, 95% CI 1.9-7.6) and high IL-6 (HR 2.5, 95% CI 1.3-4.8) were independent predictors of treatment failure. A persistent high IFN-g/IL-10 ratio at T6 conferred a 12-fold risk (HR 12.1, 95% CI 4.5-32.4) of progression to chronic kidney disease stage ≥ 3b.

Conclusion

A pre-treatment serum signature of elevated IL-6 and a high IFN-g/IL-10 ratio identifies patients with proliferative LN at substantial risk for poor outcomes. This accessible biomarker panel offers prognostic stratification beyond standard parameters and could guide risk-adapted therapeutic strategies.

Zitieren

APA

Liu, L., Luo, Y., & Yuan, H. (2026). Serum IL-6, sIL-6R, and the IFN-γ/IL-10 ratio as novel predictors of treatment resistance in proliferative lupus nephritis. Journal of Medical Biochemistry, 161-161. https://doi.org/10.5937/jomb0-63722

Vancouver

Liu L, Luo Y, Yuan H. Serum IL-6, sIL-6R, and the IFN-γ/IL-10 ratio as novel predictors of treatment resistance in proliferative lupus nephritis. Journal of Medical Biochemistry. 2026:161-161. doi:10.5937/jomb0-63722

BibTeX
@article{Liu2026,
  author = {Liu, Liu and Luo, Yating and Yuan, Huiyu},
  title = {Serum IL-6, sIL-6R, and the IFN-γ/IL-10 ratio as novel predictors of treatment resistance in proliferative lupus nephritis},
  journal = {Journal of Medical Biochemistry},
  year = {2026},
  number = {00},
  pages = {161--161},
  doi = {10.5937/jomb0-63722}
}
Kostenlos starten →